Quick answer
It depends on how far the tumor has grown into the bladder wall, on its grade and on its risk group. About 75% of bladder tumors do not invade the muscle at diagnosis.1 These are removed through the urethra, survival is favorable in most cases, and they can come back, so they need follow-up.2,5,6 When the tumor invades the muscle, treatment is bigger and is still given with curative intent.4 In your case, the answer comes from the pathology report of the TURBT.12
Why the answer is: it depends
"Bladder tumor" covers very different diseases. The vast majority start in the urothelium, the layer that lines the inside of the bladder, and most of these tumors are papillary and low grade: they tend to come back but have a relatively good prognosis. High-grade tumors that invade the wall are less common and more serious.11
The line that separates cases the most is the bladder's muscle layer. About 75% of patients have disease that does not invade the muscle, and about 25% have disease that does.1 The bladder cancer page explains each stage, from Ta to T4.
What defines how serious it is
Imaging raises the suspicion but does not define the stage. That comes from the pathology of the tissue removed in the TURBT, which is both diagnosis and first treatment.12 In the report, some points weigh more:
- Stage: whether the tumor stayed in the inner lining (Ta), reached the layer just beneath it (T1) or invaded the muscle (T2 or higher).13
- Grade: low or high. Grade helps predict whether the tumor will progress, but not whether it will come back.13
- Carcinoma in situ: a flat high-grade lesion that raises the risk when it appears alongside the tumor.3
- Number and size: several tumors and larger tumors weigh more, as does age.3
With these data, the European guideline divides non-muscle-invasive tumors into four risk groups. In a study of 3,401 patients, the chance of progression at five years was less than 1% in the lowest-risk group and more than 40% in the very high-risk group.3
The survival figures
In data from the US SEER program, 2016 to 2022, 5-year relative survival changed a lot with the stage at diagnosis:5
| Stage at diagnosis | Share of cases | 5-year relative survival |
|---|---|---|
| Inner lining only | 50% | 98% |
| Confined to the bladder | 34% | 73% |
| Lymph nodes or nearby organs | 7% | 42% |
| Spread far away | 6% | 10% |
Relative survival compares people with the cancer with people of the same age without it. Half of cases were found at the earliest stage, which is why blood in the urine needs prompt evaluation.5 These are averages across many people and do not say what will happen to you.
The chance of the tumor coming back
A non-muscle-invasive tumor is usually removed completely in the TURBT, but the bladder can form new tumors. The European guideline reports recurrence at five years in 10% to 35% of low-risk cases and in 18% to 50% of intermediate-risk cases.2
Coming back does not mean getting worse. The chance of progressing to the muscle within ten years is negligible at low risk, 7.4% to 8.5% at intermediate risk, 14% at high risk and 53.1% to 58.6% at very high risk.2 That is why treatment and the pace of cystoscopies change with the risk group.
Treatment at each stage

| Situation | What the European guideline advises |
|---|---|
| Non-invasive, low risk | TURBT and follow-up with cystoscopies2,6 |
| Non-invasive, intermediate risk | TURBT and chemotherapy into the bladder, or BCG for one year2 |
| Non-invasive, high risk | TURBT and BCG for one to three years, with a discussion about removing the bladder2 |
| Non-invasive, very high risk | Bladder removal, or BCG for those who do not want or cannot have surgery2 |
| Muscle-invasive | Systemic treatment before and after surgery, with bladder removal, or bladder-sparing treatment4 |
BCG is an immunotherapy placed into the bladder through a catheter, and chemotherapy into the bladder is given the same way.2 When the tumor does not respond to BCG, the guideline recommends offering bladder removal.2
For muscle-invasive tumors, the European guideline offers both radical cystectomy and bladder-sparing treatment, with resection, chemotherapy and radiotherapy, as curative options for those who can receive them.4 Bladder-sparing treatment suits single tumors up to T3a best, without extensive carcinoma in situ and with a bladder that works well.4
When the disease is advanced
Many people search for "end-stage bladder cancer" after a hard diagnosis. The correct name is advanced or metastatic disease, when the cancer has spread to other organs, and it still has treatment.
For those who can receive it, the European guideline recommends starting with the combination of enfortumab vedotin and pembrolizumab.7 In a study of 886 patients, this combination almost doubled median survival compared with chemotherapy.8 People who cannot receive these medicines have other chemotherapy and immunotherapy options.7
Symptom control is part of treatment. Radiotherapy helps stop bleeding and control pain, and a tube through the kidney, a nephrostomy, relieves blocked urine flow.9 The American Society of Clinical Oncology recommends that people with advanced cancer receive palliative care early, at the same time as cancer treatment.10 This care treats symptoms while the medicines treat the cancer. Family members can receive this support too.10
Follow-up with cystoscopy
After treatment, cystoscopy looks inside the bladder and finds a returning tumor early. The European guideline advises the first one three months after the TURBT, and the pace after that depends on risk:6
| Risk | If the first cystoscopy is normal |
|---|---|
| Low | Another cystoscopy nine months later, then once a year for five years6 |
| Intermediate | Every six months for two years, then once a year up to ten years6 |
| High and very high | Cystoscopy and cytology every three months for two years, every six months up to five years, then once a year for life6 |
How I approach it
In my practice, TURBT is done under general anesthesia. The catheter stays until the urine clears, with continuous bladder irrigation, and comes out before discharge. The hospital stay is usually 1 to 2 days. The pathology result takes about 1 week, and I explain it calmly at the follow-up visit, because the next step comes from it.
When bladder removal is indicated, I perform an ileal conduit (Bricker) most of the time, but the choice is made case by case with the patient, and the hospital stay is 1 week on average. The decision is made together with you, and your family takes part if you wish.
If an imaging test found a nodule or a polyp and you have not had a TURBT yet, the page on bladder nodules explains the path to diagnosis.
When to see a urologist
- If blood appears in your urine, even if only once
- If an imaging test shows a nodule, polyp or lesion in the bladder
- If you have already treated a bladder tumor and your follow-up cystoscopy is overdue
- If you pass clots or cannot urinate, contact me the same day
Send your case
If you have received a diagnosis and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
Is a bladder tumor serious?+
It depends on the stage, the grade and the risk group, which only the pathology report from the TURBT defines.12 About 75% of bladder tumors do not invade the muscle at diagnosis.1 In US data, half of cases were found while the tumor had not gone beyond the inner lining, and in this group 5-year survival was 98%.5
Can a bladder tumor be cured?+
In most tumors that do not invade the muscle, the tumor is removed through the urethra and survival is favorable, but it can come back and needs follow-up with cystoscopy.2,5,6 When it invades the muscle, removal of the bladder or bladder-sparing treatment is given with curative intent.4
Does a bladder tumor always come back?+
Not always. The European guideline reports recurrence at five years in 10% to 35% of low-risk cases and in 18% to 50% of intermediate-risk cases.2 That is why the first follow-up cystoscopy is done three months after the TURBT.6
Is a low-grade bladder tumor cancer?+
Most of the time it is a low-grade papillary urothelial carcinoma. It is a cancer, but one that tends to recur and has a relatively good prognosis.11 Grade helps predict the risk of the tumor progressing.13
What is end-stage bladder cancer?+
It is the everyday name for advanced disease, which has spread to other organs. There is still treatment with medicines, aimed at controlling the cancer and the symptoms.7,8 The American Society of Clinical Oncology recommends palliative care early, alongside cancer treatment.10
Will I need my bladder removed?+
Most people do not. Bladder removal comes in when the tumor invades the muscle, and also for non-invasive tumors at very high risk or that do not respond to BCG.1,2,4 Even when the tumor invades the muscle, bladder-sparing treatment is an option in selected cases.4
How long after the TURBT does the result come out?+
In my practice, the pathology result takes about 1 week, and I explain it at the follow-up visit, because the next step comes from it.
References
- EAU Guidelines on Non-muscle-invasive Bladder Cancer. European Association of Urology; 2026. Epidemiology and aetiology chapter. EAU
- EAU Guidelines on Non-muscle-invasive Bladder Cancer. European Association of Urology; 2026. Disease management chapter. EAU
- Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-488. PubMed
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Disease management chapter. EAU
- National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer. Data from 2016 to 2022. NCI
- EAU Guidelines on Non-muscle-invasive Bladder Cancer. European Association of Urology; 2026. Follow-up chapter. EAU
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Metastatic disease chapter. EAU
- Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. PubMed
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Quality of life and palliative care chapter. EAU
- Ferrell BR, Temel JS, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96-112. PubMed
- Wong-You-Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA. From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation. Radiographics. 2006;26(2):553-80. PubMed
- EAU Guidelines on Non-muscle-invasive Bladder Cancer. European Association of Urology; 2026. Diagnosis chapter. EAU
- EAU Guidelines on Non-muscle-invasive Bladder Cancer. European Association of Urology; 2026. Staging and classification chapter. EAU
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
